Rockland Immunochemicals and Cellaria Sign Worldwide Distribution Agreement

On February 25, 2019 Cellaria, LLC, a scientific innovator that develops revolutionary new models for cancer and other diseases, reported a new distribution partnership with Rockland Immunochemicals, Inc. (Rockland), a life science supplier and manufacturer that specializes in antibodies and antibody-based tools for research applications and assay development (Press release, Rockland, FEB 25, 2019, View Source [SID1234553932]). The agreement gives Rockland the rights to market and sell Cellaria’s high-quality next generation in-vitro disease models and cell culture media worldwide.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

With Rockland, Cellaria adds to its growing list of strategic distribution partners, expanding its global market presence and reach. Cellaria’s novel cell culture media and cancer cell models add to Rockland’s arsenal of products targeting cancer research and drug screening.

Cellaria’s cell models express different biomarkers that are directly correlated to the patient specimens used to create the models. The diversity of biomarker expression within similar categories of patients enables researchers to generate drug response and disease progression data that is highly relevant to those individual patients.

"We allow drug and cancer researchers to make much more informed decisions about which populations of patients are more likely to respond effectively to drugs that are under investigation," said David Deems, CEO of Cellaria. "Rockland’s scientific knowledge and their ability to sell cutting-edge and custom products make them a great fit to represent the innovation that we bring to market."

James Fendrick, CEO of Rockland stated, "Cellaria’s offerings will nicely complement Rockland’s existing line of cell culture products including human melanoma cell lines, fetal bovine serum, lysates and collagens. We are honored that Cellaria chose Rockland to serve as their distribution partner."